Oncorus Past Earnings Performance
Past criteria checks 0/6
Oncorus's earnings have been declining at an average annual rate of -25.8%, while the Biotechs industry saw earnings growing at 17.8% annually.
Key information
-25.8%
Earnings growth rate
67.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -290.9% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Oncorus GAAP EPS of -$0.74 misses by $0.02
Aug 04We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate
Oct 14
Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic
Jul 09Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans
May 05What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?
Feb 26Oncorus: Buy On A Dip, Potential Already Priced In At Current Levels
Feb 02Oncorus to build viral immunotherapy clinical manufacturing facility in U.S.
Jan 04We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate
Jan 04Oncorus reports Q3 results
Nov 11Revenue & Expenses BreakdownBeta
How Oncorus makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -91 | 29 | 45 |
| 31 Dec 22 | 0 | -77 | 30 | 47 |
| 30 Sep 22 | 0 | -76 | 29 | 46 |
| 30 Jun 22 | 0 | -73 | 29 | 44 |
| 31 Mar 22 | 0 | -70 | 29 | 41 |
| 31 Dec 21 | 0 | -65 | 26 | 38 |
| 30 Sep 21 | 0 | -57 | 24 | 33 |
| 30 Jun 21 | 0 | -62 | 16 | 32 |
| 31 Mar 21 | 0 | -59 | 14 | 28 |
| 31 Dec 20 | 0 | -57 | 11 | 26 |
| 30 Sep 20 | 0 | -57 | 11 | 24 |
| 30 Jun 20 | 0 | -43 | 10 | 23 |
| 31 Mar 20 | 0 | -38 | 9 | 23 |
| 31 Dec 19 | 0 | -35 | 8 | 23 |
| 31 Dec 18 | 0 | -18 | 7 | 11 |
Quality Earnings: ONCR is currently unprofitable.
Growing Profit Margin: ONCR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ONCR is unprofitable, and losses have increased over the past 5 years at a rate of 25.8% per year.
Accelerating Growth: Unable to compare ONCR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ONCR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: ONCR has a negative Return on Equity (-290.93%), as it is currently unprofitable.